Dr Rosie Upstill-Goddard

  • Bioinformatician (Clinical Research Garscube)

telephone: 0141 330 3031
email: Rosie.Upstill-Goddard@glasgow.ac.uk

Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Garscube Estate, Switchback Road, Glasgow, G61 1QH

Publications

List by: Type | Date

Jump to: 2022 | 2021 | 2020 | 2018 | 2016
Number of items: 9.

2022

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

2021

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)

Vivekanandhan, S. et al. (2021) Role of PLEXIND1/TGFβ signaling axis in pancreatic ductal adenocarcinoma progression correlates with the mutational status of KRAS. Cancers, 13(16), 4048. (doi: 10.3390/cancers13164048)

Dreyer, S. B. et al. (2021) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, (doi: 10.1097/SLA.0000000000005050) (Early Online Publication)

Griffith, B. G.C., Upstill-Goddard, R., Brunton, H., Grimes, G. R., Biankin, A. , Serrels, B., Byron, A. and Frame, M. C. (2021) FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs. Scientific Reports, 11, 229. (doi: 10.1038/s41598-020-80111-9) (PMID:33420223) (PMCID:PMC7794255)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

2020

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

2018

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

2016

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

This list was generated on Sun Oct 2 22:30:53 2022 BST.
Jump to: Articles
Number of items: 9.

Articles

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, 6738. (doi: 10.1038/s41467-021-27099-6) (PMID:34795259) (PMCID:PMC8602334)

Vivekanandhan, S. et al. (2021) Role of PLEXIND1/TGFβ signaling axis in pancreatic ductal adenocarcinoma progression correlates with the mutational status of KRAS. Cancers, 13(16), 4048. (doi: 10.3390/cancers13164048)

Dreyer, S. B. et al. (2021) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, (doi: 10.1097/SLA.0000000000005050) (Early Online Publication)

Griffith, B. G.C., Upstill-Goddard, R., Brunton, H., Grimes, G. R., Biankin, A. , Serrels, B., Byron, A. and Frame, M. C. (2021) FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs. Scientific Reports, 11, 229. (doi: 10.1038/s41598-020-80111-9) (PMID:33420223) (PMCID:PMC7794255)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

This list was generated on Sun Oct 2 22:30:53 2022 BST.